JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

148.21

+0.39%↑

Strona główna・Stock List・Cogent Biosciences Inc

Cogent Biosciences Inc

Closed

15.17 2.5

Buy Sell

Overview

Share price change

24h

Current

Min

14.94

Max

15.17

Key metrics
By Trading Economics
Income	-1.5M -74M
Profit margin	-1,582.642
Employees	205
EBITDA	1.7M -72M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+46% upside

Dividends
By Dow Jones
Next Earnings	10 lis 2025

Market Stats
By TradingEconomics
Market Cap	610M 2.3B
Previous open	12.67
Previous close	15.17

Technical Score

By Trading Central

Confidence

Bearish Evidence

4.88 / 5.87 Support & Resistance

Cogent Biosciences Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

24 paź 2025, 18:41 UTC

Earnings

Procter & Gamble to Focus on Innovation, Not Discounts, to Attract Wary Shoppers - 2nd Update

24 paź 2025, 18:31 UTC

Earnings

Correction to Procter & Gamble to Focus on Innovation

24 paź 2025, 16:25 UTC

Major Market Movers

Obook Shares Rise, Company Secures New Money Transmitter Licenses

24 paź 2025, 21:24 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

24 paź 2025, 21:24 UTC

Market Talk

Moody's Sees France With Increased Risk of Political Dysfunction -- Market Talk

24 paź 2025, 21:07 UTC

Earnings

The Score: Netflix, Amazon.com, Six Flags and More Stocks That Defined the Week -- WSJ

24 paź 2025, 20:58 UTC

Earnings

S&P 500 Climbs to New Record on Strong Earnings -- WSJ

24 paź 2025, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

24 paź 2025, 20:40 UTC

Earnings

Intel Expects Chip Shortages on Better PC Demand. Here's Why AMD Is Winning Too. -- Barrons.com

24 paź 2025, 20:24 UTC

Earnings

General Dyamics Stock Rises on Earnings. Aerospace Was a Standout. -- Barrons.com

24 paź 2025, 20:23 UTC

Earnings

General Dyamics Stock Rises on Earnings. Aerospace Was a Standout. -- Barrons.com

24 paź 2025, 20:13 UTC

Earnings

These Stocks Moved the Most Today: Intel, AMD, Ford, Deckers, Newmont, Nextracker, Booz Allen, Coinbase, and More -- Barrons.com

24 paź 2025, 20:07 UTC

Market Talk

Different-Cell Imputation Rose Proportionally in September CPI -- Market Talk

24 paź 2025, 19:40 UTC

Market Talk

Treasury Yields Mixed, Dollar Stronger Ahead of Fed Week -- Market Talk

24 paź 2025, 19:35 UTC

Market Talk

Oil Rally on U.S. Russia Sanctions Loses Steam -- Market Talk

24 paź 2025, 19:33 UTC

Earnings

IBM and Google Are Also Making Moves in Quantum. Don't Count Out the Bigger Players. -- Barrons.com

24 paź 2025, 19:29 UTC

Market Talk

U.S. Natural Gas Ends Week Higher on Weather Outlook -- Market Talk

24 paź 2025, 18:52 UTC

Earnings

Correction to GM Stock Soars to Record High. Earnings Were So Good, They Helped Ford. -- Barrons.com

24 paź 2025, 18:41 UTC

Earnings

GM Stock Soars to Record High. Earnings Were So Good, They Helped Ford. -- Barrons.com

24 paź 2025, 18:03 UTC

Earnings

Beyond Meat Stock Is on a Wild Ride. Why a Meme Rally Looks Undercooked. -- Barrons.com

24 paź 2025, 18:02 UTC

Earnings

Progressive Stock Got Hit After Earnings. It's Time to Buy One of America's Great Companies. -- Barrons.com

24 paź 2025, 18:00 UTC

Market Talk

U.S. Oil Rig Count Rises By Two to 420 -- Market Talk

24 paź 2025, 16:57 UTC

Earnings

Ford Stock Has Quadrupled Tesla's Gains. What's Behind Its Meteoric Rise. -- Barrons.com

24 paź 2025, 16:54 UTC

Market Talk

End to Canada-U.S. Trade Talks Not Seen Shifting Nearterm Outlook -- Market Talk

24 paź 2025, 16:44 UTC

Market Talk

Earnings

Amazon Retail Looks Strong as Consumer Sentiment Improves -- Market Talk

24 paź 2025, 16:39 UTC

Market Talk

Earnings

Amazon Sentiment Around AWS Seen as Improving in 3Q -- Market Talk

24 paź 2025, 16:33 UTC

Earnings

These Stocks Are Moving the Most Today: Intel, AMD, Ford, Deckers, Newmont, Nextracker, Booz Allen, Coinbase, and More -- Barrons.com

24 paź 2025, 16:23 UTC

Earnings

These Stocks Are Moving the Most Today: Intel, AMD, Ford, Deckers, Newmont, Nextracker, Booz Allen, Coinbase, and More -- Barrons.com

24 paź 2025, 16:20 UTC

Market Talk

Financial Services Roundup: Market Talk

24 paź 2025, 16:07 UTC

Earnings

Ford Stock Has Quadrupled Tesla's Gains. What's Behind Its Meteoric Rise. -- Barrons.com

Peer Comparison

Price change

Cogent Biosciences Inc Forecast

Price Target

By TipRanks

46% upside

12 Months Forecast

Average 22.09 USD 46%

High 44 USD

Low 11 USD

Based on 12 Wall Street analysts offering 12 month price targets forCogent Biosciences Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

12 ratings

Buy

Hold

Sell

Based on 12 analysts giving stock ratings to Cogent Biosciences Inc - Dist in the past 3 months.

Technical Score

By Trading Central

4.88 / 5.87Support & Resistance

Recent bearish events outweigh bullish events.

Bearish events outweigh bullish events.

All events are bearish.

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Cogent Biosciences Inc

Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.